Moreover, in the study where AD-MSCs were administered via intrathecal injection, a group of Kuzma-Kozakiewicz observed that TNF-alpha (tumor necrosis factor alpha) level was decreased while FGF basic (basic fibroblast growth factor), IL-6 (interleukin 6) and MMP-6 (Matrix Metallopeptidase 6) levels were increased in CSF after the treatment with AD-MSCs over patients with amyotrophic lateral sclerosis (ALS) (Kuzma-Kozakiewicz et al., 2018). This evidence concerns the gene IL6 and amyotrophic lateral sclerosis.